Substance / Medication

Boceprevir

Overview

Active Ingredient
boceprevir
RxNorm CUI
1102129

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

102 trials linked to this intervention

102
Total Trials
2
Recruiting
47
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
Vierling John M, Zeuzem Stefan, Poordad Fred et al. · J Hepatol · 2014
PMID: 24747798Meta-Analysis
Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.
Park C, Jiang S, Lawson K A · J Clin Pharm Ther · 2014
PMID: 24237070Meta-Analysis
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
Coppola Nicola, Pisaturo Mariantonietta, Sagnelli Caterina et al. · PLoS One · 2014
PMID: 24728219Meta-AnalysisFull text (PMC)
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.
Kieran Jennifer, Schmitz Susanne, O'Leary Aisling et al. · Clin Infect Dis · 2013
PMID: 23074309Meta-Analysis
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Sitole Mugdha, Silva Matthew, Spooner Linda et al. · Clin Ther · 2013
PMID: 23369368Meta-Analysis
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Tungol Alexandra, Rademacher Kellie, Schafer Jeremy A · J Manag Care Pharm · 2011
PMID: 22050393Meta-AnalysisFull text (PMC)
Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.
Mandorfer Mattias, Steiner Sebastian, Schwabl Philipp et al. · Wien Klin Wochenschr · 2016
PMID: 26659706RCT
Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
Johnson Mark, Borland Julie, Chen Shuguang et al. · Br J Clin Pharmacol · 2014
PMID: 24838177RCTFull text (PMC)
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Flamm Steven L, Lawitz Eric, Jacobson Ira et al. · Clin Gastroenterol Hepatol · 2013
PMID: 23064222RCT
Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.
Hammond Kyle P, Wolfe Pamela, Burton James R et al. · J Acquir Immune Defic Syndr · 2013
PMID: 23075915RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Boceprevir (substance)
SNOMED CT
698183007
UMLS CUI
C1738934
RxNorm CUI
1102129

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
102
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.